Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1035 | Thyroid (non-cancer) | ECE2018

The assessment of vitamin D3 deficiency in patients with Hashimoto’s disease and the relationship between the disease duration and 25OHD3 levels

Lizis-Kolus Katarzyna , Hubalewska-Dydejczyk Alicja , Sowa-Staszczak Anna , Skalniak Anna , Kowalska Aldona , Lizis Pawel

The observed increase in the incidence of Hashimoto’s thyroiditis (HT) requires the research on environmental factors that may initiate or model its course. There have been reports of the impact of vitamin D3 deficiency on HT development.Objective: To assess the degree of deficiency of 25OHD3 and the relationship between the disease duration and 25OHD3 levels in patients with HT.Material and methods: 310 people were enrolled i...

ea0073aep472 | Pituitary and Neuroendocrinology | ECE2021

Age and sex differences among patients with acromegaly

Anna Boguslawska , Gilis-Januszewska Aleksandra , Godlewska Magdalena , Nowak Andrzej , Starzyk Jerzy , Hubalewska-Dydejczyk Alicja

IntroductionAcromegaly is a chronic, slowly progressing disease caused in most cases by growth hormone (GH)- producing pituitary neuroendocrine tumors (PitNETs). This rare disorder is associated with a spectrum of various clinical manifestations and treatment outcomes differ between patients. The aim of this study was to evaluate the impact of age at the onset of symptoms and sex on clinical features, comorbidities, biochemical status at the diagnosis, a...

ea0073aep649 | Thyroid | ECE2021

Hyperthyroidism and exophthalmos in a patient with Erdheim–Chester disease

Mitka Kamila , Grzegorz Sokolowski , Pach Dorota , Alicja Hubalewska - Dydejczyk

We present extremely rare case of a female patient with the coincidence of hyperthyroidism, exophthalmos and Erdheim–Chester disease (a rare form of non-Langerhans cell histiocytosis, positive BRAF mutation). The patient was hospitalized due to exacerbations of the primary disease and symptoms of thyroid dysfunction. For about two months, the patient has reported increased feeling of heat, sweating, palpitations, weight loss of about 10 kg for 3 months, significant intens...

ea0093oc25 | Oral communication 4: Pituitary and Neuroendocrinology | EYES2023

The genetic background of acromegaly in a tertiary referral centre in Krakow, Poland

Bogusławska Anna , Godlewska Magdalena , Rzepka Ewelina , Korbonits Marta , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Acromegaly is the most genetically determined pituitary disease.Objectives: We studied the prevalence of syndromic disease and germline mutations (AIP, MEN1, GNAS, PRKAR1A, CDKN1b) in a cohort of unselected, consecutive patients with acromegaly.Materials and methods: A total of 133 patients (79 females, 54 males, age range 16–75 years) with somatotroph pituitary neuroendocrine tumor who were studied at t...

ea0093oc28 | Oral communication 4: Pituitary and Neuroendocrinology | EYES2023

Hepatic Steatosis Index as a non-invasive marker for liver steatosis in patients with endogenous Cushing Syndrome, ERCUSYN Krakow database

Minasyan Mari , Gamrat Aleksandra , Hubalewska-Dydejczyk Alicja , Valassi Elena , Gilis-Januszewska Aleksandra

Introduction: Liver Steatosis (LS) can be one of the metabolic complications of Cushing Syndrome (CS). The data on the impact of cortisol on liver function are very limited, according to one study the prevalence of LS in CS is 20%. However, the frequency seems to be much higher. Hepatic Steatosis Index (HSI) predicts LS based on ALT, AST, BMI, sex and co-existence of diabetes mellitus/impaired glucose intolerance. It can identify candidates for further liver examinations.<...

ea0093p20 | Guided Poster Tour 2: Miscellaneous | EYES2023

Venous thromboembolism in Cushing syndrome – A call for standardized anticoagulation regimen in hypercortisolism

Minasyan Mari , Bryk-Więzania Agata , Gamrat Aleksandra , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Cushing Syndrome (CS) is associated with a 18-fold higher risk of venous thromboembolism (VTE) when compared to the general population with the similar demographic characteristics. Despite numerous studies on hypercoagulability in CS, the unequivocal recommendations regarding timing and dosing of thromboprophylaxis in hypercortisolism are still lacking. We present a case series of patients with CS and VTE, hospitalized in the Endocrinology Department of University Hospital in ...

ea0099p452 | Calcium and Bone | ECE2024

Clustering of clinical and biochemical data for defining primary hyperparathyroidism ‘phenotypes’ and predicting parathyroid imaging results

Kucharczyk Karolina , Drynda Anna , Podlewski Jacek , Trofimiuk-Muldner Malgorzata , Hubalewska-Dydejczyk Alicja

Introduction: Primary hyperparathyroidism (PHPT) is a prevalent endocrinopathy typically identified through biochemical testing. PHPT is characterized by hypercalcemia accompanied by increased or inappropriately normal plasma parathyroid hormone (PTH) concentrations. Preoperative imaging is conducted when surgery is indicated to pinpoint parathyroid adenomas. MIBI scintigraphy is highly specific and sensitive in diagnosing PHPT, with a higher adenoma detection rate demonstrate...

ea0099p283 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Hepatic steatosis index as a non-invasive marker for liver steatosis in patients with endogenous cushing syndrome, Ercusyn krakow database

Minasyan Mari , Gamrat Aleksandra , Hubalewska-Dydejczyk Alicja , Valassi Elena , Gilis-Januszewska Aleksandra

Introduction: Liver Steatosis(LS) can be one of the metabolic complications of Cushing Syndrome(CS). The data on the impact of cortisol on liver function are very limited, and there is only one study reporting a prevalence of LS of roughly 20%. Hepatic Steatosis Index (HSI) predicts LS based on ALT, AST, BMI, sex and co-existence of diabetes mellitus/impaired glucose intolerance.Objectives: To evaluate the prevalence of LS in patients with CS at the time...

ea0099p530 | Pituitary and Neuroendocrinology | ECE2024

The analgesic effect of pasireotide in aggressive, giant pituitary neuroendocrine tumors-case series

Ciszek Karol , Bogusławska Anna , Aleksandra Komisarz-Calik Maria , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Pasireotide is a a synthetic polypeptide second-generation somatostatin analogue that can be used in the treatment of GH- and ACTH- secreting pituitary neuroendocrine tumors (PitNETs), however, there are single reports of pasireotide treatment in other subtype of PitNETs. We present a case series of aggressive, giant PitNETs treated with pasireotide alone or as multimodal therapy.Case 1: A 33-year-old male reported to the Clinic due to severe headaches a...

ea0099p185 | Late-Breaking | ECE2024

Spectacular liver tests improvement during osilodrostat treatment in patient with cushing syndrome and impaired liver function

Minasyan Mari , Bogusławska Anna , Fedak Andrzej , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

A case presents a 35 year old woman with a history of Cushing Disease (CD) diagnosed in 2014, who developed multiple complications of long lasting hypercortisolemia- obesity (BMI 55), poorly controlled diabetes mellitus (DM), heart failure, hypertension, hypercholesterolemia, mental disturbances and significant hepatic impairment. She underwent a non-radical pituitary adenoma removal in 2014 with subsequent radiotherapy in 2018. Choice of pharmacological treatment was challeng...